IRIS

Perfluorodecanoic Acid (PFDA)

CASRN 335-76-2 | DTXSID3031860

Toxicological Review of Perfluorodecanoic Acid (PFDA) and Related Salts (Final Report, 2024)

On this page:

Notice

EPA announced the release of the IRIS Toxicological Review Perfluorodecanoic Acid (PFDA) and Related Salts. The interagency comments on the IRIS Interagency Science Discussion Draft were also released.

Overview

EPA has finalized the IRIS Toxicological Review of Perfluorodecanoic Acid (PFDA) and Related Salts. This assessment addresses the potential cancer and noncancer human health effects from exposure to PFDA and related salts. EPA’s program and regional offices may use this assessment to inform decisions to protect human health.

Citation

U.S. EPA. Toxicological Review of Perfluorodecanoic Acid (PFDA) and Related Salts (Final Report, 2024). U.S. Environmental Protection Agency, Washington, DC, EPA/635/R-24/172Fa, 2024.

Top of Page


Background

Perfluorodecanoic Acid (PFDA) and its related salts are members of the group of per and polyfluoroalkyl substances (PFAS). PFAS are not naturally occurring in the environment; they are man-made compounds that have been used widely over the past several decades in consumer products and industrial applications because of their resistance to heat, oil, stains, grease, and water. Concerns about PFDA and other PFAS stem from the resistance of these compounds to hydrolysis, photolysis, and biodegradation, which leads to their persistence in the environment. PFDA has been used in stain and grease-proof coatings on food packaging, furniture, upholstery, and carpet. PFDA has also been detected in nano- and impregnation-sprays, outdoor textiles, carpet, gloves, paper-based food contact materials, ski wax, and leather. Exposure is possible via inhalation of indoor or outdoor air, ingestion of drinking water and food, and dermal contact with PFDA-containing products.

History/Chronology

Date Description
01- Nov 2019 EPA released the Systematic Review Protocol for the PFAS IRIS Assessment (Preliminary Assessment Materials). [Federal Register Notice Nov 8, 2019]
02- Jul 2020 EPA released an update to the Systematic Review Protocol for the PFBA, PFHxA, PFHxS, PFNA, and PFDA IRIS Assessments in response to public comments.
03- Mar 2022 EPA sent an interagency science consultation PFDA draft for review and comment.
04- Apr 2023 EPA released the draft IRIS Toxicological Review of Perfluorodecanoic Acid (PFDA) and Related Salts for a 60-day public comment period and external peer review. EPA also released the interagency science consultation comments from reviewers. [Federal Register Notice: April 10, 2023 ]
05- Oct 2023 EPA posted the final peer review report from the contractor on the EPA website.
06- Apr 2024 EPA submitted the revised interagency science discussion draft for final Agency and Interagency review.
07- Jul 2024 EPA posted the final report IRIS Toxicological Review of Perfluorodecanoic Acid (PFDA) and Related Salts and released the interagency science discussion draft comments on the IRIS website, and updated key IRIS values for PFDA in the IRIS database.

Top of Page

Download(s)

This download(s) is distributed solely for the purpose of pre-dissemination peer review under applicable information quality guidelines. It has not been formally disseminated by EPA. It does not represent and should not be construed to represent any Agency determination or policy.

If you have a disability and the format of any material on our web pages interferes with your ability to access the information, please reach out to us using the Contact Us about IRIS form for assistance. To enable us to respond in a manner most helpful to you, please indicate the nature of the accessibility problem, the web address of the requested material, your preferred format in which you want to receive the material (electronic format (ASCII, etc.), standard print, large print, etc.), and your contact information.


Top of Page

Quick Check

Quick check is a visual indication of the current step that this IRIS assessment has started or is in.